This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
research:project_proposal_template [2014/12/02 18:21] jduke |
research:project_proposal_template [2015/02/16 20:45] (current) rkboyce |
||
---|---|---|---|
Line 1: | Line 1: | ||
- | + | ====== Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available ====== | |
- | To create a new study: | + | |
- | + | ||
- | 1) Click the Edit button to the right of this page. Copy all the text. | + | |
- | + | ||
- | 2) Go to the [[research:protocols_in_development|Protocols under Development]] page. Click Edit. | + | |
- | + | ||
- | 3) Add the name of your study to the list. Hit Save. | + | |
- | + | ||
- | 4) Click on your new study's page. Hit edit. Paste in the text you copied and edit away! | + | |
- | + | ||
- | ====== <Your Study Name>====== | + | |
<WRAP box justify round> | <WRAP box justify round> | ||
- | **Objective:** //<summarize study objective>// | + | **Objective:** Derive data that large healthcare organizations can combine data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing |
- | **Rationale:** //<summarize study rationale>// | + | **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. |
- | **Project Lead(s):** //<initial proposers, list may grow>// | + | **Project Lead(s):** Richard D. Boyce, Matthias Samwald, Patrick Ryan, (seeking other collaborators) |
- | **Coordinating Institution(s):** //<your institution>// | + | **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna |
** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | ** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | ||
Line 26: | Line 15: | ||
**Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | ||
- | **Initial Proposal Date:** | + | **Initial Proposal Date:** 2/16/2015 |
**Launch Date:** //<fill out once finalized>// | **Launch Date:** //<fill out once finalized>// | ||
Line 37: | Line 26: | ||
===== Requirements ===== | ===== Requirements ===== | ||
- | **CDM:** //<V4 or V5 or both>// | + | **CDM:** V4 or V5 |
- | **Table Accessed:** //<e.g., person, drug_exposure, observations>// | + | **Table Accessed:** DRUG_EXPOSURE, CONCEPT_ANCESTOR, CONCEPT_RELATIONSHIP, PERSON |
**Database Dialects:** SQL Server, Postgres, Oracle | **Database Dialects:** SQL Server, Postgres, Oracle | ||
- | **Software:** //<<e.g., R>// | + | **Software:** SQL and R |
===== Code ===== | ===== Code ===== | ||
- | [[https://github.com/OHDSI/StudyProtocols]] | + | [[https://github.com/OHDSI/StudyProtocols/tree/master/Proposed%20Study%203%20-%20Incidence%20of%20exposure%20to%20PGx%20drugs|GitHub code for Proposed Study 3 - Incidence of exposure to PGx drugs]] |
===== Discussion ===== | ===== Discussion ===== | ||
Line 52: | Line 41: | ||
===== Datasets Run ===== | ===== Datasets Run ===== | ||
- | * <list your own datasets or leave blank> | + | * Truven CCAE in the IMEDS lab |
+ | * Truven MDCD in the IMEDS lab | ||
+ | * Truven MDCR in the IMEDS lab | ||
~~NOTOC~~ | ~~NOTOC~~ |